UC Davis manufactures CAR T cells on-site

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

Patients treated with CAR T-cell medicines should be monitored life-long for secondary malignancies.

June 21, 2024

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

A pioneering phase I CAR T-cell therapy trial for the treatment of glioblastoma at City of Hope, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.

June 14, 2024

Vol.50 No.24

Clinical Roundup

Innovative PET scanner could change the way lung cancer is evaluated and treatment is assessed

Scientists at UC Davis Comprehensive Cancer and the UC Davis Department of Radiology have discovered a novel way to image the unique blood supply of the lungs. Their findings, published in the Journal of Nuclear Medicine, suggest the new method could help determine if lung cancer treatment is working.

June 14, 2024

Vol.50 No.24

Drugs & Targets

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

The Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and introduce an innovative personalized cell therapy for patients in Estonia.

May 31, 2024

Vol.50 No.22

In Brief

David Tom Cooke named associate director of Office of Inclusion, Diversity, Equity and Accessibility at UC Davis

David Tom Cooke was named associate director of the Office of Inclusion, Diversity, Equity and Accessibility (IDEAL) at University of California Davis Comprehensive Cancer Center.

May 17, 2024

Vol.50 No.20

Clinical Roundup

HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial

Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas on April 24 in Nature Cancer.

April 26, 2024

Vol.50 No.17

UC Davis manufactures CAR T cells on-site

YOU MAY BE INTERESTED IN

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

Innovative PET scanner could change the way lung cancer is evaluated and treatment is assessed

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

David Tom Cooke named associate director of Office of Inclusion, Diversity, Equity and Accessibility at UC Davis

HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial

Renew today!

Subscriber content

Login